<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ANAGRELIDE HYDROCHLORIDE</span><br/>(a-na'gre-lyde)<br/><span class="topboxtradename">Agrylin<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">antiplatelet agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg, 1 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Anagrelide action appears to be related to a selective inhibition of platelet production. It inhibits platelet aggregation
         by affecting several aggregating agents (thrombin and arachidonic acid, ADP, and collagen).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Anagrelide is associated with significant decreases in platelet counts and is thought to prevent early changes in shape of
         platelets.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Essential thrombocythemia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Polycythemia vera.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety during pregnancy (category C) or lactation is not established. Hypotension, severe hepatic impairment.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Cardiovascular disease, renal function impairment, hepatic function impairment. Safety and efficacy in patients 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Essential Thrombocythemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> <img src="../images/special/greaterorequal.gif"/><i>16 y</i>, start with 0.5 mg q.i.d. or 1 mg b.i.d. times 1 wk, may increase by 0.5 mg/d qwk until platelet count is <br/><span class="impairmenttitle">Hepatic Impairment</span><br/>0.5 mg qd for 1 wk<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Make sure dosage increments do not exceed 0.5 mg/d in any 1 wk.</li>
<li>Store at 15°25° C (59°77° F) in a light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Asthenia, pain, edema (general)</span>, paresthesia, back pain, malaise, fever, chills, photosensitivity. <span class="typehead">CNS:</span> Headache, <span class="speceff-common">dizziness,</span>
<span class="speceff-life">CVA</span>, syncope, seizures. <span class="typehead">CV:</span>
<span class="speceff-common">Palpitations,</span> chest pain, tachycardia, peripheral edema, CHF, <span class="speceff-life">MI, cardiomyopathy, heart block</span>, atrial fibrillation, pericarditis, arrhythmia, hemorrhage. <span class="typehead">GI:</span>
<span class="speceff-common"> Diarrhea, abdominal pain, nausea</span>, flatulence, vomiting, dyspepsia, anorexia, pancreatitis, constipation, <span class="speceff-life">GI hemorrhage</span>, and ulceration. <span class="typehead">Hematologic:</span> Anemia, thrombocytopenia, ecchymoses, lymphedema. <span class="typehead">Respiratory:</span>
<span class="speceff-common">Dyspnea,</span> pulmonary infiltrates, <span class="speceff-life">pulmonary fibrosis</span>, pulmonary hypertension. <span class="typehead">Skin:</span> Rash, urticaria. <span class="typehead">Other:</span> Dysuria. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 70% absorbed from GI tract. Food reduces bioavailability. <span class="typehead">Onset:</span> 714 d at appropriate dose. <span class="typehead">Duration:</span> increased platelet counts were observed 4 d after discontinuing drug. <span class="typehead">Metabolism:</span> Extensively metabolized. <span class="typehead">Elimination:</span> Primarily excreted in urine as metabolites. <span class="typehead">Half-Life:</span> 1.31.8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness which is indicated by reduction of platelets for at least 4 wk to <img src="../images/special/lesserorequal.gif"/>600,000/mcL
            or 50% from baseline.
         </li>
<li>Monitor for S&amp;S of CHF or myocardial ischemia.</li>
<li>Monitor for S&amp;S of renal toxicity in patients with renal insufficiency (creatinine <img src="../images/special/greaterorequal.gif"/>2
            mg/dL).
         </li>
<li>Monitor for S&amp;S of hepatic toxicity in patients with liver functions &gt;1.5 times upper limit of normal.</li>
<li>Lab tests: Monitor platelet count q2d for first wk, weekly thereafter until maintenance dose reached; closely monitor Hgb,
            WBC count, liver function tests, and BUN and creatinine while platelet count is being lowered.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician if palpitations, fluid retention, breathing difficulty, or any other distressful symptoms develop.</li>
<li>Avoid excessive exposure to sunlight or UV light.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>